share_log

金斯瑞生物科技:CARVYKTI第二季度贸易销售净额约1.86亿美元

Genscript Bio: CARVYKTI's net sales in the second quarter of the year is approximately 0.186 billion USD.

新浪港股 ·  Jul 17 20:13

Genscript Bio (01548) announced that Legend Biotech Co., Ltd. (Legend Biotech), a non-wholly-owned subsidiary of the company whose shares are listed on the Nasdaq Global Select Market in the United States in the form of American Depositary Shares, submitted a 6-K form to the U.S. Securities and Exchange Commission on July 17, 2024 (New York time, after the Hong Kong trading session on July 17, 2024), and announced that CARVYKTI had generated net sales of approximately 0.186 billion U.S. dollars in trade sales for the quarter ended June 30, 2024, under the cooperation and license agreement signed between Legend Biotech and Janssen Biotech, Inc. (Janssen) on December 21, 2017.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment